PDF File of the Program

DATE:                    Monday, April 7, 2014


4:45 PM             Registration free to public


5:15 PM             Professor Barry M. Trost,  Tamaki Professor of Humanities and  Sciences, Stanford University,

“The Alkyne Strategy For the Synthesis of Bioactive Targets”

6:00 PM            Networking and light dinner

7:00 PM            Dr. Nicholas A. Meanwell,  Executive Director, Medicinal Chemistry, Bristol-Myers Squibb,

“The Discovery of HCV NS5A Replication Complex Inhibitors: Daclatasvir and Synergists”



Knobbe Martens Olson & Bear LLP

12790 El Camino Real, San Diego, CA 92130




PfizerKnobbe MartensBiotage


RESERVATIONS:   By Friday, April 4, 2014


Professor Barry M. Trost, Ph.D.

 Trost Born in Philadelphia, Pennsylvania, in 1941 where he began his university training at the University of Pennsylvania (BA, 1962), he obtained a Ph.D. degree in Chemistry just three years later at the Massachusetts Institute of Technology (1965).    He directly moved to the University of Wisconsin where he was promoted to Professor of Chemistry in 1969 and subsequently became the Vilas Research Professor in 1982.  He joined the faculty at Stanford as Professor of Chemistry in 1987 and became Tamaki Professor of Humanities and Sciences in 1990.  In addition, he has been Visiting Professor of Chemistry in Canada (McGill), Denmark (University of Copenhagen), France (Universities of Paris VI and Paris-Sud), Germany (Universities of Marburg, Hamburg, Munich and Heidelberg), Italy (University of Pisa), Spain (Universities
of Barcelona and Santiago de Compostela) and the UK (Cambridge University).  In 1994 he was presented with a Docteur Honoris Causa of the Université Claude-Bernard (Lyon I), France, and in 1997 a Doctor Scientiarum Honoris Causa of the Technion, Haifa, Israel. In 2006, he was appointed Honorary Professor of the Shanghai Institute of Organic Chemistry. Professor Trost’s work has been characterized by a very high order of imagination, innovation and scholarship.  He has ranged over the entire field of organic synthesis, particularly emphasizing extraordinarily novel methodology.  Further, he has repeatedly demonstrated how his innovative methodology allows for the simplification of many complex target oriented syntheses leading to natural and unnatural products of high biological activity. He has received numerous awards from around the world including the Roger Adams Award and Cope Award of the ACS.


Dr. Nicholas A. Meanwell, Ph.D.

 Meanwell Dr. Meanwell joined the medicinal chemistry department at Bristol-Myers Squibb in 1982. He has led drug discovery programs in the cardiovascular, neurosciences and virology therapeutic areas, work that has resulted in the advancement of over 25 clinical candidates for the prevention of thrombosis, the treatment of stroke and therapy for viral infections, including human immunodeficiency virus (HIV), hepatitis C virus (HCV) and respiratory syncytial virus (RSV).  Recent significant discoveries to emerge from his group include RSV fusion inhibitors, characterized as the first small molecules to interfere with the association of the 6 helical peptide bundle that is a critical step in the virus entry process, and a series of HIV attachment inhibitors that are the first small molecules described to function by interfering with the interaction between virus gp120 and the host cell CD4 receptor. BMS-663068, a phosphonooxymethyl prodrug of BMS-626529,
is currently in Phase 2 clinical trials. Significant compounds in the HCV arena include daclatasvir, a pioneering molecule that established NS5A inhibition as a clinically-relevant target and which is currently in Phase 3 clinical trials, the HCV NS3 protease inhibitor asunaprevir which incorporates the cyclopropyl acylsulfonamide moiety that has been widely adopted, and BMS-791325, a thumb site inhibitor of HCV NS5B polymerase.  The combination of daclatasvir and asunaprevir in a clinical trial conducted in HCV-infected subjects established for the first time that a HCV infection could be cured by direct acting antiviral agents in the absence of immune stimulation.